Yahoo Finance: New SPRAVATO® (esketamine nasal spray) data support robust effectiveness and show durable effect for treatment resistant depression in a real-world setting New SPRAVATO® (esketamine nasal spray) data support robust effectiveness and show durable effect for treatment resistant depression in a real-world setting Esketamine nasal spray (Spravato) monotherapy was helpful in improving symptoms of treatment-resistant depression, a randomized, double-blind trial found. Among 379 participants in the efficacy ... The American Journal of Managed Care: Esketamine Nasal Spray Shows Rapid, Durable Effectiveness in Treatment-Resistant Depression New real-world evidence on esketamine (Spravato; Janssen Pharmaceutical) nasal spray is reinforcing its role as an effective and durable treatment option for adults with treatment-resistant depression ...
Orlando Weekly: ‘Don’t give up’: VA Orlando Healthcare offers esketamine for treatment-resistant depression Esketamine is associated with a 7-point reduction in symptoms of treatment-resistant depression at week 1, with nearly 50% of patients responding by week 4, in new research. Healio: J&J seeks FDA approval of esketamine as monotherapy for treatment-resistant depression Please provide your email address to receive an email when new articles are posted on . If this indication of esketamine is approved, it would be the first monotherapy for treatment-resistant ... Nasdaq: SPRAVATO® (esketamine) approved in the U.S.
esketamine treatment, as the first and only monotherapy for adults with treatment-resistant depression SPRAVATO® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression Less-common depression treatments, including transcranial magnetic stimulation, ketamine, and esketamine, can boost the effectiveness of antidepressant medications.
